DaVita stock weighs Q2 earnings growth against reimbursement risk

Published on 10/07/2026 at 03:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DaVita stock's Q2 revenue reached USD 3.55 billion on August 4, while net income rose 33.1 percent year over year. The seven-analyst target is USD 233.43.

Aquarellmalerei der Denver-Stadtlandschaft mit Rocky Mountains im Hintergrund — Aquarell der Denver Skyline mit Rocky Mountains als Standort von DaVita Inc., ISIN US23918K1088, Illustration mit AI erstellt.

DaVita Inc. (ISIN US23918K1088) was last at USD 180.40 on the NYSE on October 6, 2026, up 0.94 percent from the prior session. The latest valuation discussion from Simply Wall St links the stock's earnings power to kidney care savings and reimbursement conditions.

Q2 growth strengthens the case

DaVita reported USD 3.55 billion of revenue for Q2 2026, the period ended June 30, 2026, while operating income reached USD 579.0 million and net income totaled USD 265.4 million, according to EarningsStory.

The same Q2 report puts revenue growth at 5.2 percent year over year and net income growth at 33.1 percent. Diluted earnings per share reached USD 4.02, giving the quarter a stronger profit profile than the revenue increase alone suggests.

Cash flow meets a leverage question

Operating cash flow reached USD 490.1 million in Q2 2026 in the standardized financial statements, while DaVita's balance-sheet total assets stood at USD 17.7 billion on June 30, 2026. The combination makes cash conversion important, but the quarter also included additional borrowing that keeps capital structure in the investor debate.

The reimbursement backdrop is the key counterweight to the earnings figures. DaVita's kidney-care model can benefit from integrated care savings, yet payer mix and revenue per treatment remain important variables for future margins, especially as treatment technology and care programs require investment.

Consensus stays above the quote

MarketBeat reported a Moderate Buy consensus on September 18, 2026, based on seven analysts. The average 12-month price target was USD 233.43, with targets ranging from USD 215 to USD 270; the average target lies 29.4 percent above the USD 180.40 quote.

MarketBeat also reported that TD Cowen upgraded DaVita from Hold to Buy and raised its target from USD 201 to USD 220 on August 7, 2026. That target revision contrasts with the stock's position 27.1 percent below its 52-week high of USD 247.49, leaving earnings execution and reimbursement discipline as the central valuation tests.

DaVita stock holds a wide range

DaVita stock was last at USD 180.40 on the NYSE at 4:00 p.m. ET on October 6, 2026. Its 52-week range was USD 101.00 to USD 247.49, and market capitalization stood at USD 11.6 billion.